KORU Medical Systems, Inc. KRMD recently announced that its state-of-the-art FreedomEdge System had received regulatory clearance in Japan for the delivery of multiple drugs. The regulatory clearance covers the delivery of multiple drugs, including CSL Behring’s Hizentra subcutaneous immunoglobulin (SCIg), Takeda Pharmaceutical’s Cuvitru SCIg and Sobi’s Aspaveli paroxysmal nocturnal hemoglobinuria (PNH). More on the News The FreedomEdge System is known for its reliability, precision, and patient-friendly design and offers convenient and efficient administration of large-volume subcutaneous therapies at home and in the clinic. The FreedomEdge System provides adjustable features to individualized treatment experiences to cater to the various demands of patients and healthcare providers. Patients can efficiently manage their therapy in a variety of locations because of its compact and portable design, which permits flexibility in treatment administration. The regulatory clearance marks a significant advancement in patient care in Japan, providing patients and healthcare providers with access to cutting-edge treatment options for SCIg and PNH. KORU Medical is likely to expand access to essential therapies with the approval of the FreedomEdge System in Japan, providing patients and healthcare professionals with a dependable and easy-to-use drug delivery platform. More on KORU’s Freedom System KORU Medical’s FREEDOM Syringe Infusion System, or the Freedom System, received its first FDA clearance in 1994. The system is used for self-administration in the home by the patient or delivered in an ambulatory infusion center by a healthcare professional. The Freedom System currently includes the FREEDOM60 and FreedomEdge Syringe Infusion Drivers, Precision Flow Rate Tubing and HIgH-Flo Subcutaneous Safety Needle Sets. The Freedom Integrated Syringe Infusion System with the FREEDOM60 Syringe Driver and Precision Flow Rate Tubing is specifically indicated for the intravenous infusion of antibiotics like Ertapenem, Meropenem, Oxacillin and Tobramycin when used according to the FDA-approved drug product labeling. Industry Prospects Per a report by Grand View Research, the global intravenous infusion pump market size was valued at $5.3 billion in 2022 and is expected to witness a growth rate of 8.3% from 2023 to 2030. The key factors driving the growth of the market include increased incidences of chronic diseases, rapid escalation seen in the geriatric population, rising surge for ambulatory infusion pumps, and the burgeoning number of people undergoing surgical procedures. Price Performance In the past six months, KRMD’s shares have lost 7.5% against the industry’s 3.4% growth. The S&P 500 has increased 16.1% in the same time frame. Zacks Investment Research Image Source: Zacks Investment Research Zacks Rank & Stocks to Consider KRMD presently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are DaVita DVA, Ecolab ECL and Universal Health Services UHS. DaVita, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. DaVita’s shares have gained 44% compared with the industry’s 20.4% growth in the past year. Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%. Ecolab’s shares have gained 33.8% against the industry’s 9.3% decline in the past year. Universal Health Services has an Earnings ESP of +2.91% and a Zacks Rank of 2, at present. UHS has an estimated earnings growth rate of 30.5% for 2024. UHS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.12%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ecolab Inc. (ECL):Free Stock Analysis Report Universal Health Services, Inc. (UHS):Free Stock Analysis Report DaVita Inc. (DVA):Free Stock Analysis Report KORU Medical Systems Inc. (KRMD):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
KORU Medical's (KRMD) FreedomEdge Gets Regulatory Nod in Japan
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...